M55 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue & Gross MarginMacroGenics generates meaningful top-line and gross profit: $157.1M TTM revenue with ~63% gross margin. A high gross margin supports continued investment in R&D and partnership economics, enabling the antibody platform to monetize collaborations and sustain core operating capacity over the medium term.
Expanded Non-dilutive FundingThe expanded ZYNYZ royalty agreement delivered an additional $60M (aggregate $130M), providing non-dilutive capital while preserving upside via remaining milestones. This enhances runway and reduces immediate equity funding needs, allowing continued clinical investment without immediate dilution pressure.
Asset Sale Improves Liquidity & FocusSelling the GMP manufacturing site for $122.5M monetizes a non-core asset, transfers manufacturing liabilities and staff, and secures supply via new agreements. The transaction materially boosts cash, lowers operating complexity, and lets management concentrate resources on clinical pipeline execution.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$70M TTM) signals continued funding needs absent milestone receipts or product revenue. Free cash flow tracking net loss suggests limited non-cash cushions; persistent burn raises dilution and refinancing risk if development progress or external funding stalls.
Elevated Leverage And Thin Equity BaseA debt-to-equity ratio near 1.72 and a thin equity base (~$21.2M) reduce financial flexibility. With ongoing losses, leverage magnifies refinancing constraints and increases the likelihood of dilutive capital raises or restrictive covenants, limiting the company's ability to pursue opportunistic investments.
Clinical And Regulatory Program RiskA prior FDA partial hold tied to serious safety events underscores material clinical risk. Although lifted, the revised protocol and added monitoring can slow enrollment, raise development costs, and alter risk/benefit profiles—any of which could delay timelines or reduce commercial potential for lorigerlimab.
MacroGenics News
M55 FAQ
What was MacroGenics Inc’s price range in the past 12 months?
Currently, no data Available
What is MacroGenics Inc’s market cap?
MacroGenics Inc’s market cap is CHF239.81M.
When is MacroGenics Inc’s upcoming earnings report date?
MacroGenics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 36 days.
How were MacroGenics Inc’s earnings last quarter?
MacroGenics Inc released its earnings results on May 13, 2026. The company reported -$0.465 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.005.
Is MacroGenics Inc overvalued?
According to Wall Street analysts MacroGenics Inc’s price is currently Undervalued.
Does MacroGenics Inc pay dividends?
MacroGenics Inc does not currently pay dividends.
What is MacroGenics Inc’s EPS estimate?
MacroGenics Inc’s EPS estimate is 0.02.
How many shares outstanding does MacroGenics Inc have?
Currently, no data Available
What happened to MacroGenics Inc’s price movement after its last earnings report?
MacroGenics Inc reported an EPS of -$0.465 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of MacroGenics Inc?
Currently, no hedge funds are holding shares in CH:M55
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
241.30%
12-Months-Change
Fundamentals
Return on Equity
-147.80%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
M55 Stock 12 Month Forecast
Average Price Target
$5.09
Options Prices
Currently, No data available
---